

Anthony E Lang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11819126/anthony-e-lang-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

551
papers

56,220
citations

108
h-index

226
g-index

573
ext. papers

66,767
ext. citations

7.9
avg, IF

7.9
L-index

#	Paper	IF	Citations
551	Neuroimaging Pearls from the MDS Congress Video Challenge. Part 1: Genetic Disorders.. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 297-310	2.2	0
550	Neuroimaging Pearls from the MDS Congress Video Challenge. Part 2: Acquired Disorders.. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 311-325	2.2	0
549	Deep Bayesian networks for uncertainty estimation and adversarial resistance of white matter hyperintensity segmentation.. <i>Human Brain Mapping</i> , 2022 ,	5.9	2
548	Common Data Elements to Facilitate Sharing and Re-use of Participant-Level Data: Assessment of Psychiatric Comorbidity Across Brain Disorders.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 816465	5	
547	Case of a Man with Hemichorea and Behavioral Changes: "A Red Herring".. <i>Movement Disorders Clinical Practice</i> , 2022 , 9, 501-507	2.2	0
546	Investigating the contribution of white matter hyperintensities and cortical thickness to empathy in neurodegenerative and cerebrovascular diseases.. <i>GeroScience</i> , 2022 , 1	8.9	
545	Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update.. <i>Movement Disorders</i> , 2022 , 37, 905-935	7	3
544	Levodopa challenge test: indications, protocol, and guide. <i>Journal of Neurology</i> , 2021 , 268, 3135-3143	5.5	16
543	Evaluating dopamine transporter imaging as an enrichment biomarker in a phase 2 Parkinson's disease trial. <i>BMC Neurology</i> , 2021 , 21, 459	3.1	3
542	Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee. <i>Neurology</i> , 2021 , 97, 942-957	6.5	11
541	Probiotics for Constipation in Parkinson Disease: A Randomized Placebo-Controlled Study. <i>Neurology</i> , 2021 , 96, e772-e782	6.5	29
540	Call the Plumber: Impaired Meningeal Lymphatic Drainage in Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 1125	7	0
539	Reply to: "The Logic and Pitfalls of Parkinson's as Brain- Versus Body-First Subtypes". <i>Movement Disorders</i> , 2021 , 36, 786-787	7	1
538	Dream Enactment Behavior Disorder Associated with Pallido-Nigro-Luysian Degeneration and Tau Proteinopathy. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 594-599	2.2	1
537	The Logic and Pitfalls of Parkinson's Disease as "Brain-First" Versus "Body-First" Subtypes. <i>Movement Disorders</i> , 2021 , 36, 594-598	7	11
536	Teaching Video NeuroImage: "Weighing" in on an Unusual Tremor. <i>Neurology</i> , 2021 , 97, e970-e971	6.5	
535	Preferences for Communication About End-of-Life Care in Atypical Parkinsonism. <i>Movement Disorders</i> , 2021 , 36, 2116-2125	7	0

534	Parkinsonism as a Sequela of SARS-CoV-2 Infection: Pure Hypoxic Injury or Additional COVID-19-Related Response?. <i>Movement Disorders</i> , 2021 , 36, 1483-1484	7	7
533	Expectations of Benefit in a Trial of a Candidate Disease-Modifying Treatment for Parkinson Disease. <i>Movement Disorders</i> , 2021 , 36, 1964-1967	7	1
532	Spinocerebellar Ataxia 40: Another Etiology Underlying Essential Tremor Syndrome. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 944-946	2.2	3
531	Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease. <i>Annals of Neurology</i> , 2021 , 90, 76-88	9.4	9
530	Hyperglycemic hemichorea presenting with normal MRI and striatal hyperdensity on CT. <i>Neurological Sciences</i> , 2021 , 42, 4341-4343	3.5	
529	Movement Disorders Associated with Hypogonadism. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 997-1011	10.1	0
528	Inhaled Levodopa as a Potential Treatment for Diphasic Dyskinesia. <i>Movement Disorders</i> , 2021 , 36, 265-266		
527	Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease. <i>Movement Disorders</i> , 2021 , 36, 171-177	7	1
526	A Distinct EEG Marker of Celiac Disease-Related Cortical Myoclonus. <i>Movement Disorders</i> , 2021 , 36, 999-1005	10.5	3
525	Gut Microbial Ecosystem in Parkinson Disease: New Clinicobiological Insights from Multi-Omics. <i>Annals of Neurology</i> , 2021 , 89, 546-559	9.4	34
524	DYT-TUBB4A (DYT4 Dystonia): New Clinical and Genetic Observations. <i>Neurology</i> , 2021 , 96, e1887-e1897	10.5	1
523	Suggestibility as a valuable criterion for laboratory-supported definite functional movement disorders. <i>Clinical Neurophysiology Practice</i> , 2021 , 6, 103-108	3.8	1
522	Botulinum Toxin-Associated Prolonged Remission of Idiopathic Cervical Dystonia. <i>Canadian Journal of Neurological Sciences</i> , 2021 , 1-5	1	0
521	Improved Segmentation of the Intracranial and Ventricular Volumes in Populations with Cerebrovascular Lesions and Atrophy Using 3D CNNs. <i>Neuroinformatics</i> , 2021 , 19, 597-618	3.2	5
520	Parkinson's Disease and COVID-19: Do We Need to Be More Patient?. <i>Movement Disorders</i> , 2021 , 36, 277	7	5
519	Bilingualism in Parkinson's disease: Relationship to cognition and quality of life. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2021 , 43, 199-212	2.1	1
518	Is clinical assessment enough? Moving towards early differentiation of neurodegenerative parkinsonisms. <i>Brain</i> , 2021 , 144, 1040-1042	11.2	0
517	Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based Nosology. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3

516	Short-term deceleration capacity of heart rate: a sensitive marker of cardiac autonomic dysfunction in idiopathic Parkinson's disease. <i>Clinical Autonomic Research</i> , 2021 , 31, 729-736	4.3	0
515	Irreversible extreme freezing of gait after dopamine agonist withdrawal. <i>Clinical Case Reports (discontinued)</i> , 2021 , 9, e04712	0.7	0
514	The Discovery of α -Synuclein in Lewy Pathology of Parkinson's Disease: The Inspiration of a Revolution. <i>Movement Disorders Clinical Practice</i> , 2021 , 8, 1189-1193	2.2	1
513	Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. <i>Nature Medicine</i> , 2021 , 27, 1451-1457	50.5	16
512	Contribution of rare variant associations to neurodegenerative disease presentation. <i>Npj Genomic Medicine</i> , 2021 , 6, 80	6.2	1
511	Association of apolipoprotein E variation with cognitive impairment across multiple neurodegenerative diagnoses. <i>Neurobiology of Aging</i> , 2021 , 105, 378.e1-378.e9	5.6	1
510	Neuroimaging Advances in Parkinson's Disease and Atypical Parkinsonian Syndromes. <i>Frontiers in Neurology</i> , 2020 , 11, 572976	4.1	16
509	Age-Related Parkinsonian Signs in Microdeletion 22q11.2. <i>Movement Disorders</i> , 2020 , 35, 1239-1245	7	2
508	The evidence for multidisciplinary care in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2020 , 20, 539-549	4.3	3
507	Parkinson's Disease, NOTCH3 Genetic Variants, and White Matter Hyperintensities. <i>Movement Disorders</i> , 2020 , 35, 2090-2095	7	8
506	Forecasts for the Attainment of Major Research Milestones in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 1047-1055	5.3	3
505	GDNF and Parkinson's Disease: Where Next? A Summary from a Recent Workshop. <i>Journal of Parkinson's Disease</i> , 2020 , 10, 875-891	5.3	28
504	Initiation of pharmacological therapy in Parkinson's disease: when, why, and how. <i>Lancet Neurology</i> , 2020 , 19, 452-461	24.1	51
503	Outcome measurement in functional neurological disorder: a systematic review and recommendations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 638-649	5.5	37
502	PET Tau Imaging and Motor Impairments Differ Between Corticobasal Syndrome and Progressive Supranuclear Palsy With and Without Alzheimer's Disease Biomarkers. <i>Frontiers in Neurology</i> , 2020 , 11, 574	4.1	5
501	Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?. <i>Neurology</i> , 2020 , 94, 481-494	6.5	60
500	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency?. <i>Parkinsonism and Related Disorders</i> , 2020 , 71, 44-45	3.6	3
499	Mild dopa-responsive dystonia in heterozygous tyrosine hydroxylase mutation carrier: Evidence of symptomatic enzyme deficiency? Response from the authors. <i>Parkinsonism and Related Disorders</i> , 2020 , 74, 80	3.6	2

498	Adult-onset neuronal intranuclear inclusion disease mimicking Fragile X-associated tremor-ataxia syndrome in ethnic Chinese patients. <i>Parkinsonism and Related Disorders</i> , 2020 , 74, 25-27	3.6	7
497	Isolated Ear Clicks with Partial Voluntary Control. <i>Tremor and Other Hyperkinetic Movements</i> , 2020 , 10, 55	2	
496	Diagnosing functional neurological disorder: seeing the whole picture. <i>CNS Spectrums</i> , 2020 , 1-8	1.8	2
495	Integrated Therapy for Functional Movement Disorders: Time for a Change. <i>Movement Disorders Clinical Practice</i> , 2020 , 7, 169-174	2.2	12
494	Interhemispheric pathways in agenesis of the corpus callosum and Parkinson's disease. <i>Brain Stimulation</i> , 2020 , 13, 360-362	5.1	2
493	Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease. <i>Clinics in Geriatric Medicine</i> , 2020 , 36, 105-118	3.8	13
492	Video-tutorial for the Movement Disorder Society criteria for progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2020 , 78, 200-203	3.6	4
491	The Cortical Basal ganglia Functional Scale (CBFS): Development and preliminary validation. <i>Parkinsonism and Related Disorders</i> , 2020 , 79, 121-126	3.6	4
490	Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD). <i>Journal of Parkinsons Disease</i> , 2020 , 10, 1561-1569	5.3	3
489	Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance. <i>Movement Disorders</i> , 2020 , 35, 1755-1764	7	21
488	Initiating pharmacotherapy in early Parkinson's disease. <i>Lancet Neurology</i> , 2020 , 19, 643-644	24.1	
487	The retina as a window to the basal ganglia: Systematic review of the potential link between retinopathy and hyperkinetic disorders in diabetes. <i>Parkinsonism and Related Disorders</i> , 2020 , 80, 194-198	3.6	5
486	Cognitive impairment in Parkinson's disease: Associations between subjective and objective cognitive decline in a large longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2020 , 80, 127-132	3.6	3
485	Telemedicine in Movement Disorders: Leçons du COVID-19. <i>Movement Disorders</i> , 2020 , 35, 1893-1896	7	16
484	Helicobacter pylori Eradication in Parkinson's Disease: A Randomized Placebo-Controlled Trial. <i>Movement Disorders</i> , 2020 , 35, 2250-2260	7	20
483	Validation of the movement disorder society criteria for the diagnosis of 4-repeat tauopathies. <i>Movement Disorders</i> , 2020 , 35, 171-176	7	23
482	What Is the Role of a Specialist Assessment Clinic for FND? Lessons From Three National Referral Centers. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020 , 32, 79-84	2.7	25
481	The Interaction Between Neuroinflammation and ßAmyloid in Cognitive Decline in Parkinson's Disease. <i>Molecular Neurobiology</i> , 2020 , 57, 492-501	6.2	12

480	Primary brain calcification due to a homozygous MYORG mutation causing isolated paroxysmal kinesigenic dyskinesia. <i>Brain</i> , 2020 , 143, e36	11.2	6
479	Reply to "Studying reproducibility of data-driven Parkinson's disease subtypes". <i>Parkinsonism and Related Disorders</i> , 2019 , 66, 245-246	3.6	
478	Orthostatic hypotension and dementia incidence: links and implications. <i>Neuropsychiatric Disease and Treatment</i> , 2019 , 15, 2181-2194	3.1	10
477	Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Clinical Autonomic Research</i> , 2019 , 29, 603-614	4.3	7
476	Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. <i>Translational Neurodegeneration</i> , 2019 , 8, 28	10.3	42
475	Tics and functional tic-like movements: Can we tell them apart?. <i>Neurology</i> , 2019 , 93, 750-758	6.5	45
474	Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease. <i>New England Journal of Medicine</i> , 2019 , 380, 315-324	59.2	145
473	Diagnostic delay in Parkinson's disease caused by PRKN mutations. <i>Parkinsonism and Related Disorders</i> , 2019 , 63, 217-220	3.6	11
472	Treatment of Palatal Tremor. <i>Current Clinical Neurology</i> , 2019 , 179-183	0.1	1
471	Parkinson's disease in the Western Pacific Region. <i>Lancet Neurology</i> , 2019 , 18, 865-879	24.1	55
470	The clinical significance of lower limb tremors. <i>Parkinsonism and Related Disorders</i> , 2019 , 65, 165-171	3.6	5
469	Hiding in Plain Sight: Functional Neurological Disorders in the News. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2019 , 31, 361-367	2.7	11
468	Dystonia and Parkinson's disease: What is the relationship?. <i>Neurobiology of Disease</i> , 2019 , 132, 104462	7.5	37
467	Paroxysmal Asymmetric Dystonic Arm Posturing-A Less Recognized but Characteristic Manifestation of ATP1A3-related disease. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 312-315	2.2	11
466	Isolated Abdominal Motor Seizures of Mesial Parietal Origin: Epileptic Belly Dancing?. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 396-399	2.2	2
465	Jumping to overcome freezing of gait while turning in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019 , 64, 349-351	3.6	2
464	The Parkinson's disease e-diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019 , 34, 676-681	7	28
463	How to apply the movement disorder society criteria for diagnosis of progressive supranuclear palsy. <i>Movement Disorders</i> , 2019 , 34, 1228-1232	7	56

462	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , 2019 , 92, 329-337	6.5	144
461	Repurposing drugs to treat L-DOPA-induced dyskinesia in Parkinson's disease. <i>Neuropharmacology</i> , 2019 , 147, 11-27	5.5	18
460	Amantadine for Gait Dysfunction in Pantothenate Kinase-Associated Neurodegeneration. <i>Canadian Journal of Neurological Sciences</i> , 2019 , 46, 782-784	1	2
459	Dancing Dorsal Quadrilaterals-Organic or Functional?-Reply. <i>JAMA Neurology</i> , 2019 , 76, 985-986	17.2	
458	ADCY5-Related Dyskinesia: Improving Clinical Detection of an Evolving Disorder. <i>Movement Disorders Clinical Practice</i> , 2019 , 6, 512-520	2.2	18
457	Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer's Disease, Parkinson's Disease, and Healthy Controls. <i>Frontiers in Neuroscience</i> , 2019 , 13, 1259	5.1	17
456	Clinical and neural responses to cognitive behavioral therapy for functional tremor. <i>Neurology</i> , 2019 , 93, e1787-e1798	6.5	43
455	Corticobasal degeneration. <i>International Review of Neurobiology</i> , 2019 , 149, 87-136	4.4	12
454	Dancing Dorsal Quadrilaterals: A Novel Peripherally Induced Movement Disorder. <i>JAMA Neurology</i> , 2019 , 76, 351-354	17.2	8
453	Successful pallidotomy for post-hyperglycemic hemichorea-ballism. <i>Parkinsonism and Related Disorders</i> , 2019 , 61, 228-230	3.6	5
452	Soft signs in movement disorders: friends or foes?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 961-962	5.5	13
451	Decreased pallidal vesicular monoamine transporter type 2 availability in Parkinson's disease: The contribution of the nigropallidal pathway. <i>Neurobiology of Disease</i> , 2019 , 124, 176-182	7.5	10
450	Gut-brain axis and the spread of β synuclein pathology: Vagal highway or dead end?. <i>Movement Disorders</i> , 2019 , 34, 307-316	7	98
449	Therapeutic trial design for frontotemporal dementia and related disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019 , 90, 412-423	5.5	16
448	Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. <i>Movement Disorders</i> , 2018 , 33, 960-965	7	10
447	Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. <i>Movement Disorders</i> , 2018 , 33, 660-677	7	174
446	Pallidal deep brain stimulation modulates cortical excitability and plasticity. <i>Annals of Neurology</i> , 2018 , 83, 352-362	9.4	36
445	Infantile-onset hand dystonia with intellectual disability: Clues to mutations. <i>Neurology</i> , 2018 , 90, 333-335		3

444	Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease. <i>Cmaj</i> , 2018 , 190, E50-E52	3.5	4
443	What is "essential" about essential tremor? A diagnostic placeholder. <i>Movement Disorders</i> , 2018 , 33, 58-61		28
442	Educational Needs and Considerations for a Visual Educational Tool to Discuss Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 66-74	2.2	5
441	Oculogyric crises in PLA2G6 associated neurodegeneration. <i>Parkinsonism and Related Disorders</i> , 2018 , 52, 111-112	3.6	7
440	Functional neurological disorders in Parkinson disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, 566-571	5.5	49
439	Impaired emotion processing in functional (psychogenic) tremor: A functional magnetic resonance imaging study. <i>NeuroImage: Clinical</i> , 2018 , 17, 179-187	5.3	50
438	Altered gut microbiome and metabolome in patients with multiple system atrophy. <i>Movement Disorders</i> , 2018 , 33, 174-176	7	34
437	[F]AV-1451 binding to neuromelanin in the substantia nigra in PD and PSP. <i>Brain Structure and Function</i> , 2018 , 223, 589-595	4	29
436	Essential tremor plus is more common than essential tremor: Insights from the reclassification of a cohort of patients with lower limb tremor. <i>Parkinsonism and Related Disorders</i> , 2018 , 56, 109-110	3.6	33
435	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. <i>Parkinsonism and Related Disorders</i> , 2018 , 56, 102-106	3.6	42
434	Emotion Detection Deficits and Decreased Empathy in Patients with Alzheimer's Disease and Parkinson's Disease Affect Caregiver Mood and Burden. <i>Frontiers in Aging Neuroscience</i> , 2018 , 10, 120	5.3	34
433	Sleep-related motor and behavioral disorders: Recent advances and new entities. <i>Movement Disorders</i> , 2018 , 33, 1042-1055	7	6
432	Typical features of Parkinson disease and diagnostic challenges with microdeletion 22q11.2. <i>Neurology</i> , 2018 , 90, e2059-e2067	6.5	25
431	Comment on "Is it Useful to Classify PSP and CBD as Different Disorders?". <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 564-565	2.2	4
430	Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice. <i>Movement Disorders</i> , 2018 , 33, 1195-1203	7	3
429	Movement disorder society criteria for clinically established early Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1643-1646	7	67
428	Validation of the MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2018 , 33, 1601-1608	7	101
427	Current Concepts in Diagnosis and Treatment of Functional Neurological Disorders. <i>JAMA Neurology</i> , 2018 , 75, 1132-1141	17.2	252

426	Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. <i>Journal of Parkinsons Disease</i> , 2018 , 8, 131-139	5.3	7
425	Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. <i>Journal of Neural Transmission</i> , 2018 , 125, 1373-1379	4.3	14
424	Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2018 , 56, 58-64	3.6	47
423	Lymphatic vasculature in human dural superior sagittal sinus: Implications for neurodegenerative proteinopathies. <i>Neuroscience Letters</i> , 2018 , 665, 18-21	3.3	22
422	Parkinson Diseases in the 2020s and Beyond: Replacing Clinico-Pathologic Convergence With Systems Biology Divergence. <i>Journal of Parkinsons Disease</i> , 2018 , 8, S59-S64	5.3	38
421	Serum Inflammatory Profile for the Discrimination of Clinical Subtypes in Parkinson's Disease. <i>Frontiers in Neurology</i> , 2018 , 9, 1123	4.1	11
420	Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease. <i>Journal of Parkinsons Disease</i> , 2018 , 8, 503-510	5.3	12
419	Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts. <i>Annals of Neurology</i> , 2018 , 84, 797-811	9.4	122
418	Systematic review of movement disorders and oculomotor abnormalities in Whipple's disease. <i>Movement Disorders</i> , 2018 , 33, 1700-1711	7	11
417	Neuropsychiatric expression and catatonia in 22q11.2 deletion syndrome: An overview and case series. <i>American Journal of Medical Genetics, Part A</i> , 2018 , 176, 2146-2159	2.5	13
416	Myoclonus-dystonia: classification, phenomenology, pathogenesis, and treatment. <i>Current Opinion in Neurology</i> , 2018 , 31, 484-490	7.1	43
415	Action Myoclonus and Seizure in Kufor-Rakeb Syndrome. <i>Movement Disorders Clinical Practice</i> , 2018 , 5, 195-199	2.2	11
414	Precision medicine for disease modification in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017 , 13, 119-126	15	103
413	Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease. <i>Movement Disorders</i> , 2017 , 32, 610-614	7	14
412	Essential pitfalls in "essential" tremor. <i>Movement Disorders</i> , 2017 , 32, 325-331	7	52
411	Positron emission tomography imaging of tau pathology in progressive supranuclear palsy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017 , 37, 3150-3160	7.3	38
410	Pedunculopontine nucleus stimulation in progressive supranuclear palsy: a randomised trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017 , 88, 613-616	5.5	16
409	Oculogyric crises: A review of phenomenology, etiology, pathogenesis, and treatment. <i>Movement Disorders</i> , 2017 , 32, 193-202	7	23

408	Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. <i>Movement Disorders</i> , 2017 , 32, 319-324	7	111
407	Adult motor phenotype differentiates Dravet syndrome from Lennox-Gastaut syndrome and links SCN1A to early onset parkinsonian features. <i>Epilepsia</i> , 2017 , 58, e44-e48	6.4	21
406	Which ante mortem clinical features predict progressive supranuclear palsy pathology?. <i>Movement Disorders</i> , 2017 , 32, 995-1005	7	88
405	Common Myths in the Use of Levodopa in Parkinson Disease: When Clinical Trials Misinform Clinical Practice. <i>JAMA Neurology</i> , 2017 , 74, 633-634	17.2	40
404	Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. <i>Movement Disorders</i> , 2017 , 32, 853-864	7	840
403	Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts. <i>Lancet Neurology, The</i> , 2017 , 16, 620-629	24.1	98
402	Tremor-Dominant Pantothenate Kinase-associated Neurodegeneration. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 772-774	2.2	5
401	Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. <i>Lancet Neurology, The</i> , 2017 , 16, 552-563	24.1	209
400	Tracking the course of prodromal Parkinson's disease. <i>Brain</i> , 2017 , 140, 259-262	11.2	3
399	Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts. <i>Translational Neurodegeneration</i> , 2017 , 6, 8	10.3	121
398	Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease. <i>Movement Disorders</i> , 2017 , 32, 893-903	7	21
397	Neuroimaging and clinical features in adults with a 22q11.2 deletion at risk of Parkinson's disease. <i>Brain</i> , 2017 , 140, 1371-1383	11.2	30
396	Parkinson disease. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17013	51.1	1700
395	Placebos in clinical trials: unravelling a complex phenomenon. <i>Lancet Neurology, The</i> , 2017 , 16, 28-29	24.1	5
394	Alternating Hemiplegia of Childhood as a New Presentation of Adenylate Cyclase 5-Mutation-Associated Disease: A Report of Two Cases. <i>Journal of Pediatrics</i> , 2017 , 181, 306-308.e1	3.6	19
393	The Ontario Neurodegenerative Disease Research Initiative (ONDRI). <i>Canadian Journal of Neurological Sciences</i> , 2017 , 44, 196-202	1	44
392	Caffeine as symptomatic treatment for Parkinson disease (CafEPD): A randomized trial. <i>Neurology</i> , 2017 , 89, 1795-1803	6.5	69
391	Deconstructing normal pressure hydrocephalus: Ventriculomegaly as early sign of neurodegeneration. <i>Annals of Neurology</i> , 2017 , 82, 503-513	9.4	95

390	Progressive ataxia and palatal tremor: Two autopsy cases of a novel tauopathy. <i>Movement Disorders</i> , 2017 , 32, 1465-1473	7	13
389	Recurrent Impulse Control Disorder Associated with Rasagiline Treatment of Parkinson's Disease. <i>Canadian Journal of Neurological Sciences</i> , 2017 , 44, 447-448	1	3
388	Is there even such a thing as "idiopathic normal pressure hydrocephalus"?. <i>Annals of Neurology</i> , 2017 , 82, 1032	9.4	2
387	A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III). <i>Annals of Clinical and Translational Neurology</i> , 2017 , 4, 360-368	5.3	46
386	Will New Genetic Techniques Like Exome Sequencing Obviate the Need for Clinical Expertise? No. <i>Movement Disorders Clinical Practice</i> , 2017 , 4, 39-41	2.2	3
385	Fatigue in Parkinson's disease: The contribution of cerebral metabolic changes. <i>Human Brain Mapping</i> , 2017 , 38, 283-292	5.9	21
384	Motor Phenotype in Neurodegenerative Disorders: Gait and Balance Platform Study Design Protocol for the Ontario Neurodegenerative Research Initiative (ONDRI). <i>Journal of Alzheimer's Disease</i> , 2017 , 59, 707-721	4.3	40
383	Whole-genome sequencing suggests mechanisms for 22q11.2 deletion-associated Parkinson's disease. <i>PLoS ONE</i> , 2017 , 12, e0173944	3.7	11
382	Asymmetric neuromodulation of motor circuits in Parkinson's disease: The role of subthalamic deep brain stimulation. <i>Surgical Neurology International</i> , 2017 , 8, 261	1	13
381	The long-term outcome of orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 167-72	5.5	29
380	Unusual tremor syndromes: know in order to recognise. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1191-1203	5.5	35
379	Fatigue in Parkinson's disease: report from a multidisciplinary symposium. <i>Npj Parkinson's Disease</i> , 2016 , 2,	9.7	45
378	α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. <i>Trends in Neurosciences</i> , 2016 , 39, 750-762	13.3	92
377	Learning More from Finger Tapping in Parkinson's Disease: Up and Down from Dyskinesia to Bradykinesia. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 184-187	2.2	5
376	Parkinson disease in 2015: Evolving basic, pathological and clinical concepts in PD. <i>Nature Reviews Neurology</i> , 2016 , 12, 65-6	15	113
375	Cortical Plasticity Induction by Pairing Subthalamic Nucleus Deep-Brain Stimulation and Primary Motor Cortical Transcranial Magnetic Stimulation in Parkinson's Disease. <i>Journal of Neuroscience</i> , 2016 , 36, 396-404	6.6	47
374	Mutation analysis of CHCHD2 in Canadian patients with familial Parkinson's disease. <i>Neurobiology of Aging</i> , 2016 , 38, 217.e7-217.e8	5.6	15
373	Orthostatic hypotension, cerebral hypoperfusion, and visuospatial deficits in Lewy body disorders. <i>Parkinsonism and Related Disorders</i> , 2016 , 22, 80-6	3.6	24

372	Characterization of Movement Disorder Phenomenology in Genetically Proven, Familial Frontotemporal Lobar Degeneration: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016 , 11, e0153852	3.7	17
371	Disrupted Nodal and Hub Organization Account for Brain Network Abnormalities in Parkinson's Disease. <i>Frontiers in Aging Neuroscience</i> , 2016 , 8, 259	5.3	35
370	Neurogenic orthostatic hypotension and supine hypertension in Parkinson's disease and related synucleinopathies: prioritisation of treatment targets. <i>Lancet Neurology, The</i> , 2016 , 15, 954-966	24.1	78
369	Technology in Parkinson's disease: Challenges and opportunities. <i>Movement Disorders</i> , 2016 , 31, 1272-827		305
368	Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 116-124	2.2	13
367	Paroxysmal Hemiballism/Hemichorea Resulting from Transient Ischemic Attacks. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 303-305	2.2	5
366	Contribution of insula in Parkinson's disease: A quantitative meta-analysis study. <i>Human Brain Mapping</i> , 2016 , 37, 1375-92	5.9	30
365	Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects. <i>Movement Disorders</i> , 2016 , 31, 290-6	7	54
364	Appendectomy in mid and later life and risk of Parkinson's disease: A population-based study. <i>Movement Disorders</i> , 2016 , 31, 1243-7	7	38
363	'Under pressure': is there a link between orthostatic hypotension and cognitive impairment in Synucleinopathies?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 1311-1321	5.5	49
362	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study. <i>Brain</i> , 2016 , 139, 2050-62	11.2	38
361	The new definition and diagnostic criteria of Parkinson's disease. <i>Lancet Neurology, The</i> , 2016 , 15, 546-8	24.1	61
360	Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. <i>Parkinsonism and Related Disorders</i> , 2016 , 28, 41-48	3.6	23
359	Abolishing the 1-year rule: How much evidence will be enough?. <i>Movement Disorders</i> , 2016 , 31, 1623-1627		35
358	Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease. <i>Movement Disorders Clinical Practice</i> , 2016 , 3, 53-58	2.2	1
357	Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. <i>Movement Disorders</i> , 2016 , 31, 538-46	7	65
356	Long-term double-blinded unilateral pedunculopontine area stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2016 , 31, 1570-1574	7	44
355	Practical guidelines for managing adults with 22q11.2 deletion syndrome. <i>Genetics in Medicine</i> , 2015 , 17, 599-609	8.1	154

354	Effects of subthalamic nucleus stimulation on motor cortex plasticity in Parkinson disease. <i>Neurology</i> , 2015 , 85, 425-32	6.5	34
353	Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 968-71	3.6	21
352	Phenotype-specific diagnosis of functional (psychogenic) movement disorders. <i>Current Neurology and Neuroscience Reports</i> , 2015 , 15, 32	6.6	78
351	Plasma near-infrared spectroscopy for diagnosis of idiopathic Parkinson's disease: the SPIN-PD study. <i>Biomarkers in Medicine</i> , 2015 , 9, 89-97	2.3	4
350	Parkinson's disease. <i>Lancet, The</i> , 2015 , 386, 896-912	40	2652
349	Mutations in XPR1 cause primary familial brain calcification associated with altered phosphate export. <i>Nature Genetics</i> , 2015 , 47, 579-81	36.3	176
348	Response to clozapine in a clinically identifiable subtype of schizophrenia. <i>British Journal of Psychiatry</i> , 2015 , 206, 484-91	5.4	44
347	Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. <i>Movement Disorders</i> , 2015 , 30, 500-9	7	151
346	Mutation analysis of CHCHD10 in different neurodegenerative diseases. <i>Brain</i> , 2015 , 138, e380	11.2	67
345	Behavioral effects of levodopa. <i>Movement Disorders</i> , 2015 , 30, 90-102	7	52
344	Mutation analysis of patients with neurodegenerative disorders using NeuroX array. <i>Neurobiology of Aging</i> , 2015 , 36, 545.e9-14	5.6	24
343	Salience network and parahippocampal dopamine dysfunction in memory-impaired Parkinson disease. <i>Annals of Neurology</i> , 2015 , 77, 269-80	9.4	62
342	Imaging changes associated with cognitive abnormalities in Parkinson's disease. <i>Brain Structure and Function</i> , 2015 , 220, 2249-61	4	35
341	Disease-modifying strategies for Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1442-50	7	146
340	MDS research criteria for prodromal Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1600-11	7	645
339	Dystonic Pseudo Foot Drop. <i>Movement Disorders Clinical Practice</i> , 2015 , 2, 295-298	2.2	3
338	Successful treatment of functional palatal tremor: Insights into pathogenesis and management. <i>Movement Disorders</i> , 2015 , 30, 875-6	7	7
337	Movement disorders and other motor abnormalities in adults with 22q11.2 deletion syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2015 , 167A, 639-45	2.5	43

336	Genome-wide variant by serum urate interaction in Parkinson's disease. <i>Annals of Neurology</i> , 2015 , 78, 731-41	9.4	8
335	Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. <i>Annals of Neurology</i> , 2015 , 78, 248-57	9.4	190
334	Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [(11) C]-(+)-PHNO and [(11) C]raclopride positron emission tomography imaging study. <i>Human Brain Mapping</i> , 2015 , 36, 2592-601	5.9	14
333	Vascular Parkinsonism: deconstructing a syndrome. <i>Movement Disorders</i> , 2015 , 30, 886-94	7	63
332	Imaging Striatal Microglial Activation in Patients with Parkinson's Disease. <i>PLoS ONE</i> , 2015 , 10, e0138721	3.7	67
331	Clinical correlations with Lewy body pathology in LRRK2-related Parkinson disease. <i>JAMA Neurology</i> , 2015 , 72, 100-5	17.2	191
330	Helicobacter pylori infection is associated with worse severity of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015 , 21, 221-5	3.6	78
329	Unfreezing of gait in patients with Parkinson's disease. <i>Lancet Neurology, The</i> , 2015 , 14, 675-7	24.1	16
328	Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. <i>Neurology</i> , 2015 , 84, 609-16	6.5	110
327	MDS clinical diagnostic criteria for Parkinson's disease. <i>Movement Disorders</i> , 2015 , 30, 1591-601	7	2371
326	Placebo effect of medication cost in Parkinson disease: a randomized double-blind study. <i>Neurology</i> , 2015 , 84, 794-802	6.5	87
325	In pursuit of prodromal Parkinson's disease. <i>Lancet Neurology, The</i> , 2015 , 14, 27-8	24.1	1
324	Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. <i>Movement Disorders</i> , 2015 , 30, 150-9	7	71
323	Implications of nocturnal symptoms towards the early diagnosis of Parkinson's disease. <i>Journal of Neural Transmission</i> , 2014 , 121 Suppl 1, S49-57	4.3	18
322	Combined insular and striatal dopamine dysfunction are associated with executive deficits in Parkinson's disease with mild cognitive impairment. <i>Brain</i> , 2014 , 137, 565-75	11.2	98
321	Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , 2014 , 1, 67-69	2.2	13
320	Uncovering the role of the insula in non-motor symptoms of Parkinson's disease. <i>Brain</i> , 2014 , 137, 2143-54	14.2	106
319	Designing clinical trials for dystonia. <i>Neurotherapeutics</i> , 2014 , 11, 117-27	6.4	14

318	The treatment of dystonic tremor: a systematic review. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014 , 85, 759-69	5.5	76
317	Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. <i>Neurotherapeutics</i> , 2014 , 11, 6-23	6.4	89
316	Initiating dopaminergic treatment in Parkinson's disease. <i>Lancet, The</i> , 2014 , 384, 1164-6	4.0	13
315	Longitudinal quantitative MRI in multiple system atrophy and progressive supranuclear palsy. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 222-5	3.6	21
314	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. <i>Movement Disorders</i> , 2014 , 29, 454-62	7	290
313	Bilateral pallidal stimulation for sargoglycan epsilon negative myoclonus. <i>Parkinsonism and Related Disorders</i> , 2014 , 20, 915-8	3.6	14
312	From psychogenic movement disorder to functional movement disorder: it's time to change the name. <i>Movement Disorders</i> , 2014 , 29, 849-52	7	101
311	Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial. <i>Lancet Neurology, The</i> , 2014 , 13, 676-85	24.1	197
310	Antecollis and levodopa-responsive parkinsonism are late features of Dravet syndrome. <i>Neurology</i> , 2014 , 82, 2250-1	6.5	44
309	Peroxisomal D-bifunctional protein deficiency: three adults diagnosed by whole-exome sequencing. <i>Neurology</i> , 2014 , 82, 963-8	6.5	53
308	Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. <i>Neurology</i> , 2014 , 82, 1402-9	6.5	32
307	Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. <i>Neurology</i> , 2014 , 82, 1791-7	6.5	108
306	'Don't delay, start today': delaying levodopa does not delay motor complications. <i>Brain</i> , 2014 , 137, 2628-30	10.2	22
305	Global investigation and meta-analysis of the C9orf72 (G4C2) _n repeat in Parkinson disease. <i>Neurology</i> , 2014 , 83, 1906-13	6.5	49
304	Alimentary, my dear Watson? The challenges of enteric synuclein as a Parkinson's disease biomarker. <i>Movement Disorders</i> , 2014 , 29, 444-50	7	64
303	Tremor in Spinocerebellar Ataxia Type 12. <i>Movement Disorders Clinical Practice</i> , 2014 , 1, 76-78	2.2	5
302	Subthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better. <i>Movement Disorders</i> , 2014 , 29, 1751-6	7	56
301	Functional/psychogenic movement disorders: do we know what they are?. <i>Movement Disorders</i> , 2014 , 29, 1696-7; discussion 1699-701	7	12

300	Pharmacological treatment of Parkinson disease: a review. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 1670-83	27.4	816
299	Dopamine-agonists and impulsivity in Parkinson's disease: impulsive choices vs. impulsive actions. <i>Human Brain Mapping</i> , 2014 , 35, 2499-506	5.9	59
298	The prion hypothesis in Parkinson's disease: Braak to the future. <i>Acta Neuropathologica Communications</i> , 2013 , 1, 2	7.3	155
297	Clinicopathological review of pallidonigrolyusian atrophy. <i>Movement Disorders</i> , 2013 , 28, 274-81	7	12
296	Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. <i>Movement Disorders</i> , 2013 , 28, 1980-6	7	31
295	AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. <i>Movement Disorders</i> , 2013 , 28, 1838-46	7	107
294	Commentary. <i>Movement Disorders</i> , 2013 , 28, 1806-7	7	1
293	Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. <i>Neurogenetics</i> , 2013 , 14, 11-22	3	111
292	HemiballismBlemichorea 2013 , 151-161		2
291	βSynuclein oligomers and clinical implications for Parkinson disease. <i>Annals of Neurology</i> , 2013 , 73, 155-69.4	6.4	209
290	The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2013 , 43, 151-65.5	5.5	11
289	Timing of deep brain stimulation in Parkinson disease: a need for reappraisal?. <i>Annals of Neurology</i> , 2013 , 73, 565-75	9.4	53
288	Criteria for the diagnosis of corticobasal degeneration. <i>Neurology</i> , 2013 , 80, 496-503	6.5	1004
287	Caffeine consumption and risk of dyskinesia in CALM-PD. <i>Movement Disorders</i> , 2013 , 28, 380-3	7	41
286	Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. <i>Lancet Neurology, The</i> , 2013 , 12, 514-24	24.1	108
285	Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. <i>Annals of Neurology</i> , 2013 , 73, 537-45	9.4	98
284	Phenomenology and classification of dystonia: a consensus update. <i>Movement Disorders</i> , 2013 , 28, 863-73	7.3	1217
283	Trial designs used to study neuroprotective therapy in Parkinson's disease. <i>Movement Disorders</i> , 2013 , 28, 86-95	7	45

282	Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 130-5	5.5	86
281	Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients. <i>Neurology</i> , 2013 , 80, 1698-701	6.5	152
280	Mutations in GNAL cause primary torsion dystonia. <i>Nature Genetics</i> , 2013 , 45, 88-92	36.3	229
279	Voxel-based imaging of translocator protein 18 kDa (TSPO) in high-resolution PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013 , 33, 348-50	7.3	9
278	Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. <i>JAMA Neurology</i> , 2013 , 70, 1359-66	17.2	107
277	Impact of mild cognitive impairment on health-related quality of life in Parkinson's disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2013 , 36, 67-75	2.6	36
276	Reply to Drs. Kurlan, Fasano, and Evans: A clinically useful definition of stereotypies. <i>Movement Disorders</i> , 2013 , 28, 405-6	7	
275	The value of GRE, ADC and routine MRI in distinguishing Parkinsonian disorders. <i>Canadian Journal of Neurological Sciences</i> , 2013 , 40, 389-402	1	23
274	Reply to letter: Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. <i>Movement Disorders</i> , 2013 , 28, 408	7	
273	Stereotypies: a critical appraisal and suggestion of a clinically useful definition. <i>Movement Disorders</i> , 2012 , 27, 179-85	7	74
272	Acquired neurosyphilis presenting as movement disorders. <i>Movement Disorders</i> , 2012 , 27, 690-5	7	34
271	A case of neurosyphilis presenting with myoclonus, cerebellar ataxia, and speech disturbance. <i>Movement Disorders</i> , 2012 , 27, 794	7	10
270	Stem cell therapy for Parkinson's disease. <i>Annals of Neurology</i> , 2012 , 71, 283; author reply 284	9.4	4
269	Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. <i>Lancet Neurology</i> , 2012 , 11, 643-50	24.1	37
268	Psychogenic facial movement disorders: clinical features and associated conditions. <i>Movement Disorders</i> , 2012 , 27, 1544-51	7	73
267	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. <i>Journal of Medical Genetics</i> , 2012 , 49, 721-6	5.8	78
266	Associated movement disorders in orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012 , 83, 725-9	5.5	36
265	Caffeine for treatment of Parkinson disease: a randomized controlled trial. <i>Neurology</i> , 2012 , 79, 651-8	6.5	197

264	Investigation of c9orf72 in 4 neurodegenerative disorders. <i>Archives of Neurology</i> , 2012 , 69, 1583-90		83
263	Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. <i>Movement Disorders</i> , 2012 , 27, 1392-7	7	94
262	Movement disorders in patients with diabetes mellitus. <i>Journal of the Neurological Sciences</i> , 2012 , 314, 5-11	3.2	28
261	Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [¹¹ C] FLB-457 and PET study. <i>Neurobiology of Disease</i> , 2012 , 48, 519-25	7.5	101
260	Premotor Parkinson's disease: concepts and definitions. <i>Movement Disorders</i> , 2012 , 27, 608-16	7	108
259	Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. <i>Movement Disorders</i> , 2012 , 27, 1186-90	7	72
258	Parkinsonism 2012 , 2326-2333		
257	Psychogenic dystonia 2012 , 307-319		
256	Overview of the Medical Treatment of the Non-Motor and Non-Dopaminergic Features of Parkinson's Disease 2011 , 394-408		
255	Dopamine Dysregulation Syndrome 2011 , 202-214		1
254	Psychosis in Parkinson's Disease 2011 , 170-182		
253	Depression in Parkinson's Disease 2011 , 183-192		
252	Anxiety Syndromes and Panic Attacks 2011 , 193-201		1
251	Neurobiology of Impulse Control Disorders in Parkinson's Disease 2011 , 215-232		
250	Development of a non-motor fluctuation assessment instrument for Parkinson disease. <i>Parkinson's Disease</i> , 2011 , 2011, 2927-19	2.6	21
249	The Emerging Entity of Pre-Motor Parkinson's Disease 2011 , 93-104		1
248	Pain and Paresthesia in Parkinson's Disease 2011 , 315-332		2
247	Thalamic neuronal and EMG activity in psychogenic dystonia compared with organic dystonia. <i>Movement Disorders</i> , 2011 , 26, 1348-52	7	16

246	Psychogenic movement disorders: past developments, current status, and future directions. <i>Movement Disorders</i> , 2011 , 26, 1175-86	7	38
245	Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. <i>Movement Disorders</i> , 2011 , 26, 608-13	7	16
244	Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials. <i>Movement Disorders</i> , 2011 , 26, 1464-76	7	32
243	A critical appraisal of the premotor symptoms of Parkinson's disease: potential usefulness in early diagnosis and design of neuroprotective trials. <i>Movement Disorders</i> , 2011 , 26, 775-83	7	101
242	Expanding the phenomenology of benign hereditary chorea: evolution from chorea to myoclonus and dystonia. <i>Movement Disorders</i> , 2011 , 26, 2296-7	7	12
241	Early-onset tardive dyskinesia in a neuroleptic-naive patient exposed to low-dose quetiapine. <i>Movement Disorders</i> , 2011 , 26, 2297-8	7	5
240	The curious case of phenocopies in families with genetic Parkinson's disease. <i>Movement Disorders</i> , 2011 , 26, 1793-802	7	34
239	Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. <i>Movement Disorders</i> , 2011 , 26, 2427-31	7	32
238	Impulse control disorders in Parkinson disease: a multicenter case--control study. <i>Annals of Neurology</i> , 2011 , 69, 986-96	9.4	296
237	Movement disorders on YouTube--caveat spectator. <i>New England Journal of Medicine</i> , 2011 , 365, 1160-159.2		59
236	Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. <i>Journal of Neurosurgery</i> , 2011 , 114, 1428-31	3.2	16
235	Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. <i>Archives of Neurology</i> , 2011 , 68, 1550-6		304
234	Unilateral subdural motor cortex stimulation improves essential tremor but not Parkinson's disease. <i>Brain</i> , 2011 , 134, 2096-105	11.2	73
233	Surgical correction of kyphosis in patients with camptocormia due to Parkinson's disease: a retrospective evaluation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011 , 82, 364-8	5.5	33
232	Comprehensive mutational analysis of LRRK2 reveals variants supporting association with autosomal dominant Parkinson's disease. <i>Journal of Human Genetics</i> , 2011 , 56, 671-5	4.3	9
231	Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future. <i>Nature Medicine</i> , 2010 , 16, 1223-6	50.5	63
230	The nature and time course of cortical activation following subthalamic stimulation in Parkinson's disease. <i>Cerebral Cortex</i> , 2010 , 20, 1926-36	5.1	100
229	Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. <i>Archives of Neurology</i> , 2010 , 67, 589-95		988

228	Therapy of the Motor Features of Parkinson's Disease. <i>Blue Books of Neurology</i> , 2010 , 34, 252-272		
227	LRRK2 and Parkin mutations in a family with parkinsonism-Lack of genotype-phenotype correlation. <i>Neurobiology of Aging</i> , 2010 , 31, 721-2	5.6	6
226	Event-related desynchronization of motor cortical oscillations in patients with multiple system atrophy. <i>Experimental Brain Research</i> , 2010 , 206, 1-13	2.3	8
225	Extrastriatal dopaminergic dysfunction in tourette syndrome. <i>Annals of Neurology</i> , 2010 , 67, 170-81	9.4	84
224	Dystonia in complex regional pain syndrome type I. <i>Annals of Neurology</i> , 2010 , 67, 412-4	9.4	21
223	Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. <i>Annals of Neurology</i> , 2010 , 68, 18-27	9.4	270
222	Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. <i>Annals of Neurology</i> , 2010 , 68, 963-8	9.4	105
221	Involvement of the cerebellothalamocortical pathway in Parkinson disease. <i>Annals of Neurology</i> , 2010 , 68, 816-24	9.4	90
220	Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 578-86	7	319
219	The nonmotor symptoms of Parkinson's disease--an overview. <i>Movement Disorders</i> , 2010 , 25 Suppl 1, S123-30	7	103
218	A comparison of depression, anxiety, and health status in patients with progressive supranuclear palsy and multiple system atrophy. <i>Movement Disorders</i> , 2010 , 25, 1077-81	7	90
217	Neuronal intranuclear inclusion disease: two cases of dopa-responsive juvenile parkinsonism with drug-induced dyskinesia. <i>Movement Disorders</i> , 2010 , 25, 1274-9	7	17
216	Effect of movement frequency on repetitive finger movements in patients with Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 252; author reply 253	7	3
215	Double-blind study of pramipexole, a new partial dopamine agonist, in early Parkinson's disease. <i>Movement Disorders</i> , 2010 , 25, 738-46	7	27
214	Characteristic head drops and axial extension in advanced chorea-acanthocytosis. <i>Movement Disorders</i> , 2010 , 25, 1487-91	7	42
213	The grasp reflex: a symptom in need of treatment. <i>Movement Disorders</i> , 2010 , 25, 2479-85	7	6
212	Standard guidelines for publication of deep brain stimulation studies in Parkinson's disease (Guide4DBS-PD). <i>Movement Disorders</i> , 2010 , 25, 1530-7	7	17
211	Long-term effect of unilateral pallidotomy on levodopa-induced dyskinesia. <i>Movement Disorders</i> , 2010 , 25, 1496-8	7	16

210	Urate as a predictor of the rate of clinical decline in Parkinson disease. <i>Archives of Neurology</i> , 2009 , 66, 1460-8		265
209	When and how should treatment be started in Parkinson disease?. <i>Neurology</i> , 2009 , 72, S39-43	6.5	46
208	Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?. <i>Neuropsychopharmacology</i> , 2009 , 34, 2758-66	8.7	126
207	Overview of the extranigral aspects of Parkinson disease. <i>Archives of Neurology</i> , 2009 , 66, 167-72		128
206	Selective enhancement of rapid eye movement sleep by deep brain stimulation of the human pons. <i>Annals of Neurology</i> , 2009 , 66, 110-4	9.4	91
205	Dopaminergic transplantation for Parkinson's disease: current status and future prospects. <i>Annals of Neurology</i> , 2009 , 66, 591-6	9.4	70
204	Stimulation of the subthalamic nucleus and impulsivity: release your horses. <i>Annals of Neurology</i> , 2009 , 66, 817-24	9.4	199
203	Cerebral blood flow changes induced by pedunculopontine nucleus stimulation in patients with advanced Parkinson's disease: a [(15)O] H2O PET study. <i>Human Brain Mapping</i> , 2009 , 30, 3901-9	5.9	88
202	Impairments of speed and amplitude of movement in Parkinson's disease: a pilot study. <i>Movement Disorders</i> , 2009 , 24, 1001-8	7	71
201	Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. <i>Movement Disorders</i> , 2009 , 24, 1366-74	7	117
200	Hereditary parkinsonism: Parkinson disease look-alikes--an algorithm for clinicians to "PARK" genes and beyond. <i>Movement Disorders</i> , 2009 , 24, 2042-58	7	49
199	A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. <i>Movement Disorders</i> , 2009 , 24, 2081-90	7	44
198	ATP13A2 variants in early-onset Parkinson's disease patients and controls. <i>Movement Disorders</i> , 2009 , 24, 2104-11	7	54
197	A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. <i>Movement Disorders</i> , 2009 , 24, 2370-8	7	10
196	Myoclonus in complex regional pain syndrome. <i>Movement Disorders</i> , 2009 , 24, 314-6; author reply 316	7	18
195	Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , 2009 , 22, 430-6	7.1	205
194	Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson's Disease?. <i>Neuropsychopharmacology</i> , 2009 , 34, 2758-66	8.7	65
193	Non-dopaminergic treatments in development for Parkinson's disease. <i>Lancet Neurology</i> , The , 2008 , 7, 927-38	24.1	92

192	A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. <i>Brain</i> , 2008 , 131, 2720-8	11.2	392
191	Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. <i>Archives of Neurology</i> , 2008 , 65, 716-23		251
190	Reduced intracortical and interhemispheric inhibitions in corticobasal syndrome. <i>Journal of Clinical Neurophysiology</i> , 2008 , 25, 304-12	2.2	20
189	The spectrum of orolingual tremor--a proposed classification system. <i>Movement Disorders</i> , 2008 , 23, 159-67	7	34
188	The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins. <i>Movement Disorders</i> , 2008 , 23, 290-4	7	14
187	A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. <i>Movement Disorders</i> , 2008 , 23, 297-9	7	221
186	Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. <i>Movement Disorders</i> , 2008 , 23, 653-9; quiz 776	7	109
185	Levodopa-related motor complications--phenomenology. <i>Movement Disorders</i> , 2008 , 23 Suppl 3, S509-14		71
184	Reply: The variability of levodopa response in Parkinson's disease: Is sensitization reversible?. <i>Movement Disorders</i> , 2008 , 23, 925-925	7	
183	rCBF changes associated with PPN stimulation in a patient with Parkinson's disease: a PET study. <i>Movement Disorders</i> , 2008 , 23, 1051-1054	7	48
182	Electrophysiological features of myoclonus-dystonia. <i>Movement Disorders</i> , 2008 , 23, 2055-61	7	34
181	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. <i>Movement Disorders</i> , 2008 , 23, 2129-70	7	3156
180	Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. <i>Lancet Neurology</i> , 2008 , 7, 583-90	24.1	1075
179	Movement Disorders: Diagnosis and Assessment 2008 , 293-325		3
178	Motor and non-motor fluctuations. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , 2007 , 84, 157-84	3	4
177	Characterization of REM-sleep associated ponto-geniculo-occipital waves in the human pons. <i>Sleep</i> , 2007 , 30, 823-7	1.1	80
176	Antidepressants and psychosis in Parkinson disease: a case series. <i>International Journal of Geriatric Psychiatry</i> , 2007 , 22, 601-4	3.9	18
175	Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. <i>Movement Disorders</i> , 2007 , 22, 41-7	7	802

174	Unilateral versus bilateral tasks in early asymmetric Parkinson's disease: differential effects on bradykinesia. <i>Movement Disorders</i> , 2007 , 22, 328-33	7	28
173	Gait abnormalities in psychogenic movement disorders. <i>Movement Disorders</i> , 2007 , 22, 395-9	7	107
172	Punding prevalence in Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 1179-81	7	102
171	Interhemispheric and ipsilateral connections in Parkinson's disease: relation to mirror movements. <i>Movement Disorders</i> , 2007 , 22, 813-21	7	88
170	Refinement of the DYT15 locus in myoclonus dystonia. <i>Movement Disorders</i> , 2007 , 22, 888-92	7	38
169	Orthostatic tremor in progressive supranuclear palsy. <i>Movement Disorders</i> , 2007 , 22, 1192-4	7	14
168	Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2007 , 22, 990-7	7	87
167	Sustained relief of dystonia following cessation of deep brain stimulation. <i>Movement Disorders</i> , 2007 , 22, 1958-62	7	49
166	Benign hereditary chorea revisited: a journey to understanding. <i>Movement Disorders</i> , 2007 , 22, 2297-305; quiz 2452	7	43
165	Subdural motor cortex stimulation in Parkinson's disease does not modify movement-related rCBF pattern. <i>Movement Disorders</i> , 2007 , 22, 2113-6	7	30
164	Reversible dopamine agonist induced anterocollis in a multiple system atrophy patient. <i>Movement Disorders</i> , 2007 , 22, 2292-3	7	10
163	Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. <i>Movement Disorders</i> , 2007 , 22, 2409-17	7	174
162	GDNF in Parkinson's disease: the perils of post-hoc power. <i>Journal of Neuroscience Methods</i> , 2007 , 163, 193-6	3	11
161	Deciphering the role of heterozygous mutations in genes associated with parkinsonism. <i>Lancet Neurology</i> , 2007 , 6, 652-62	24.1	242
160	Diagnosing psychogenic movement disorders-which criteria should be used in clinical practice?. <i>Nature Clinical Practice Neurology</i> , 2007 , 3, 134-5		15
159	Fixed dystonia unresponsive to pallidal stimulation improved by motor cortex stimulation. <i>Neurology</i> , 2007 , 69, 1062-3; author reply 1063	6.5	5
158	Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. <i>Archives of Neurology</i> , 2007 , 64, 212-6		289
157	The progression of Parkinson disease: a hypothesis. <i>Neurology</i> , 2007 , 68, 948-52	6.5	96

156	Involvement of the basal ganglia and cerebellar motor pathways in the preparation of self-initiated and externally triggered movements in humans. <i>Journal of Neuroscience</i> , 2007 , 27, 6029-36	6.6	54
155	Manganese-induced Parkinsonism associated with methcathinone (Ephedrone) abuse. <i>Archives of Neurology</i> , 2007 , 64, 886-9		87
154	Neuronal firing rates and patterns in the globus pallidus internus of patients with cervical dystonia differ from those with Parkinson's disease. <i>Journal of Neurophysiology</i> , 2007 , 98, 720-9	3.2	109
153	The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007 , 66, 251-7	3.1	88
152	The many faces of corticobasal degeneration. <i>Parkinsonism and Related Disorders</i> , 2007 , 13 Suppl 3, S336-40	3.40	78
151	GDNF in treatment of Parkinson's disease: response to editorial. <i>Lancet Neurology, The</i> , 2006 , 5, 200-2	24.1	29
150	Neuroprotection in Parkinson's disease: and now for something completely different?. <i>Lancet Neurology, The</i> , 2006 , 5, 990-1	24.1	19
149	Homozygous and heterozygous PINK1 mutations: considerations for diagnosis and care of Parkinson's disease patients. <i>Movement Disorders</i> , 2006 , 21, 875-9	7	23
148	Crossroads in GDNF therapy for Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21, 136-41	7	145
147	Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. <i>Movement Disorders</i> , 2006 , 21, 1578-94	7	91
146	Deep brain stimulation for Parkinson's disease. <i>Movement Disorders</i> , 2006 , 21 Suppl 14, S168-70	7	53
145	Deep brain stimulation: preoperative issues. <i>Movement Disorders</i> , 2006 , 21 Suppl 14, S171-96	7	208
144	Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. <i>Movement Disorders</i> , 2006 , 21 Suppl 14, S290-304	7	651
143	Development of dyskinesias in a 5-year trial of ropinirole and L-dopa. <i>Movement Disorders</i> , 2006 , 21, 1844-50		116
142	Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. <i>Movement Disorders</i> , 2006 , 21, 1941-6	7	207
141	Rapidly progressive sporadic dentatorubral pallidoluyian atrophy with intracytoplasmic inclusions and no CAG repeat expansion. <i>Movement Disorders</i> , 2006 , 21, 2251-4	7	10
140	Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. <i>Annals of Neurology</i> , 2006 , 59, 459-66	9.4	785
139	Interface between tauopathies and synucleinopathies: a tale of two proteins. <i>Annals of Neurology</i> , 2006 , 59, 449-58	9.4	204

138	Cortical and spinal abnormalities in psychogenic dystonia. <i>Annals of Neurology</i> , 2006 , 59, 825-34	9.4	169
137	Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. <i>Journal of Neurophysiology</i> , 2006 , 96, 3248-56	3.2	413
136	Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. <i>Brain</i> , 2006 , 129, 1059-69.2		250
135	Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. <i>Neurology</i> , 2006 , 66, 845-51	6.5	328
134	Criteria for deep-brain stimulation in Parkinson's disease: review and analysis. <i>Expert Review of Neurotherapeutics</i> , 2006 , 6, 1695-705	4.3	55
133	Psychogenic Dystonia. <i>Medical Psychiatry</i> , 2006 , 277-288		
132	Apraxia in movement disorders. <i>Brain</i> , 2005 , 128, 1480-97	11.2	201
131	Psychogenic movement disorders. <i>Current Opinion in Neurology</i> , 2005 , 18, 399-404	7.1	41
130	Progress in clinical neurosciences: a forum on the early management of Parkinson's disease. <i>Canadian Journal of Neurological Sciences</i> , 2005 , 32, 277-86	1	3
129	Analysis of the glucocerebrosidase gene in Parkinson's disease. <i>Movement Disorders</i> , 2005 , 20, 367-70	7	93
128	Pallidal deep brain stimulation influences both reflexive and voluntary saccades in Huntington's disease. <i>Movement Disorders</i> , 2005 , 20, 371-7	7	23
127	Alterations of striatal neurons in benign hereditary chorea. <i>Movement Disorders</i> , 2005 , 20, 1353-7	7	54
126	Firing rates of pallidal neurons are similar in Huntington's and Parkinson's disease patients. <i>Experimental Brain Research</i> , 2005 , 166, 230-6	2.3	66
125	Identification of a VPS13A founder mutation in French Canadian families with chorea-acanthocytosis. <i>Neurogenetics</i> , 2005 , 6, 151-8	3	30
124	Selected genetically engineered models relevant to human neurodegenerative disease 2005 , 176-195		1
123	Structural and functional magnetic resonance imaging in neurodegenerative diseases 2005 , 253-289		1
122	Corticobasal degeneration 2005 , 682-696		
121	Neurophysiology of Parkinson's disease, levodopa-induced dyskinesias, dystonia, Huntington's disease and myoclonus 2005 , 227-250		

120	Approach to the patient presenting with parkinsonism 2005 , 551-560		
119	Current and potential treatments of Parkinson's disease 2005 , 612-622		
118	Multiple system atrophy 2005 , 623-662		2
117	Psychiatric symptoms in patients with Parkinson disease presenting for deep brain stimulation surgery. <i>Journal of Neurosurgery</i> , 2005 , 103, 246-51	3.2	41
116	Antidepressant treatment outcomes of psychogenic movement disorder. <i>Journal of Clinical Psychiatry</i> , 2005 , 66, 1529-34	4.6	102
115	Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. <i>Archives of Neurology</i> , 2004 , 61, 1898-904		131
114	Clinical findings in a large family with a parkin ex3delta40 mutation. <i>Archives of Neurology</i> , 2004 , 61, 701-4		23
113	Progressive ataxia and palatal tremor (PAPT): clinical and MRI assessment with review of palatal tremors. <i>Brain</i> , 2004 , 127, 1252-68	11.2	107
112	Single pulse stimulation of the human subthalamic nucleus facilitates the motor cortex at short intervals. <i>Journal of Neurophysiology</i> , 2004 , 92, 1937-43	3.2	44
111	Involvement of human thalamus in the preparation of self-paced movement. <i>Brain</i> , 2004 , 127, 2717-31	11.2	91
110	Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. <i>Lancet Neurology</i> , 2004 , 3, 309-16	24.1	256
109	Bilateral globus pallidus stimulation for Huntington's disease. <i>Annals of Neurology</i> , 2004 , 56, 290-4	9.4	179
108	Chorein detection for the diagnosis of chorea-acanthocytosis. <i>Annals of Neurology</i> , 2004 , 56, 299-302	9.4	162
107	Gestes antagonistes in psychogenic dystonia. <i>Movement Disorders</i> , 2004 , 19, 331-2	7	27
106	Sporadic case of dentatorubral pallidoluysian atrophy with no CAG repeat expansion and no intranuclear inclusions. <i>Movement Disorders</i> , 2004 , 19, 580-3	7	9
105	Rapidly progressive behavioral changes and parkinsonism in a 68-year-old man. <i>Movement Disorders</i> , 2004 , 19, 534-43	7	4
104	Bilateral globus pallidus internus deep brain stimulation in tardive dyskinesia: a case report. <i>Movement Disorders</i> , 2004 , 19, 969-72	7	80
103	Subthalamic nucleus deep brain stimulation for parkinson's disease after successful pallidotomy: clinical and electrophysiological observations. <i>Movement Disorders</i> , 2004 , 19, 1209-14	7	43

102	Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. <i>Movement Disorders</i> , 2004 , 19, 656-62	7	208
101	Distribution, type, and origin of Parkin mutations: review and case studies. <i>Movement Disorders</i> , 2004 , 19, 1146-57	7	194
100	Neuronal activity in the globus pallidus of multiple system atrophy patients. <i>Movement Disorders</i> , 2004 , 19, 1485-92	7	6
99	The perioperative management of Parkinson's disease revisited. <i>Neurologic Clinics</i> , 2004 , 22, 367-77	4.5	24
98	Genetic association study of PINK1 coding polymorphisms in Parkinson's disease. <i>Neuroscience Letters</i> , 2004 , 372, 226-9	3.3	28
97	Primary dystonia is more responsive than secondary dystonia to pallidal interventions: outcome after pallidotomy or pallidal deep brain stimulation. <i>Neurosurgery</i> , 2004 , 54, 613-19; discussion 619-21	3.2	224
96	Insights into brain function through the examination of art: the influence of neurodegenerative diseases. <i>NeuroReport</i> , 2004 , 15, 933-7	1.7	8
95	Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease. <i>Clinical Neuropharmacology</i> , 2004 , 27, 90-2	1.4	22
94	Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists. <i>Archives of Neurology</i> , 2004 , 61, 97-102		152
93	Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. <i>Journal of Neurosurgery</i> , 2003 , 99, 489-95	3.2	257
92	Short and long latency afferent inhibition in Parkinson's disease. <i>Brain</i> , 2003 , 126, 1883-94	11.2	214
91	Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. <i>Neurosurgery</i> , 2003 , 53, 1095-102; discussion 1102-5	3.2	69
90	Long-term follow-up of thalamic deep brain stimulation for essential and parkinsonian tremor. <i>Neurology</i> , 2003 , 61, 1601-4	6.5	174
89	The fragile X premutation presenting as essential tremor. <i>Archives of Neurology</i> , 2003 , 60, 117-21		145
88	The cerebellothalamocortical pathway in essential tremor. <i>Neurology</i> , 2003 , 60, 1985-7	6.5	83
87	Motor cortical stimulation for parkinsonism in multiple system atrophy. <i>Archives of Neurology</i> , 2003 , 60, 1554-8		36
86	Hemiballism: revisiting a classic disorder. <i>Lancet Neurology</i> , 2003 , 2, 661-8	24.1	173
85	Neurodegenerative disease and the evolution of art: the effects of presumed corticobasal degeneration in a professional artist. <i>Movement Disorders</i> , 2003 , 18, 294-302	7	28

84	Unique form of propriospinal myoclonus as a possible complication of an enteropathogenic toxin. <i>Movement Disorders</i> , 2003 , 18, 942-8	7	17
83	Corticobasal degeneration: selected developments. <i>Movement Disorders</i> , 2003 , 18 Suppl 6, S51-6	7	34
82	Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: a functional MRI case study. <i>Movement Disorders</i> , 2003 , 18, 1508-16	7	160
81	Posttraumatic painful torticollis. <i>Movement Disorders</i> , 2003 , 18, 1482-91	7	68
80	Pallidal neuronal activity: implications for models of dystonia. <i>Annals of Neurology</i> , 2003 , 53, 480-8	9.4	223
79	Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. <i>Annals of Neurology</i> , 2003 , 54 Suppl 5, S15-9	9.4	423
78	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. <i>Annals of Neurology</i> , 2003 , 54, 93-101	9.4	691
77	Benign hereditary chorea: clinical, genetic, and pathological findings. <i>Annals of Neurology</i> , 2003 , 54, 244-7.4	9.4	81
76	Psychogenic movement disorders. <i>Canadian Journal of Neurological Sciences</i> , 2003 , 30 Suppl 1, S94-100	1	67
75	Natural history of Oppenheim's dystonia (DYT1) in Israel. <i>Journal of Child Neurology</i> , 2003 , 18, 325-30	2.5	27
74	Combination of dopamine transporter and D2 receptor SPECT in the diagnostic evaluation of PD, MSA, and PSP. <i>Movement Disorders</i> , 2002 , 17, 303-12	7	159
73	Deep brain stimulation for Parkinson's disease: patient selection and evaluation. <i>Movement Disorders</i> , 2002 , 17 Suppl 3, S94-101	7	121
72	Predicting motor decline and disability in Parkinson disease: a systematic review. <i>Archives of Neurology</i> , 2002 , 59, 1724-8		146
71	Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. <i>Journal of Neurosurgery</i> , 2002 , 97, 1152-66	3.2	222
70	Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 287, 455-63	27.4	408
69	Long-term hardware-related complications of deep brain stimulation. <i>Neurosurgery</i> , 2002 , 50, 1268-74; discussion 1274-6	3.2	272
68	Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. <i>Brain</i> , 2002 , 125, 1196-209	11.2	545
67	Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. <i>Clinical Neuropharmacology</i> , 2002 , 25, 111-4	1.4	108

66	Long-term Hardware-related Complications of Deep Brain Stimulation. <i>Neurosurgery</i> , 2002 , 50, 1268-1276	196
65	Pathophysiology of the Internal Segment of the Globus Pallidus in Parkinson Disease. <i>Advances in Behavioral Biology</i> , 2002 , 15-21	
64	Sleepiness and Sleep Attacks in Parkinson Disease. <i>Advances in Behavioral Biology</i> , 2002 , 385-390	
63	Myoclonus in parkinsonian disorders. <i>Advances in Neurology</i> , 2002 , 89, 77-83	6
62	Essential palatal tremor. <i>Movement Disorders</i> , 2001 , 16, 1202-3	7 3
61	69-year-old man with gait disturbance and Parkinsonism. <i>Movement Disorders</i> , 2001 , 16, 548-61	7 1
60	Impairment of motor cortex activation and deactivation in Parkinson's disease. <i>Clinical Neurophysiology</i> , 2001 , 112, 600-7	4.3 71
59	Lidocaine and muscimol microinjections in subthalamic nucleus reverse Parkinsonian symptoms. <i>Brain</i> , 2001 , 124, 2105-18	11.2 141
58	Deep brain stimulator electrodes used for lesioning: proof of principle. <i>Neurosurgery</i> , 2001 , 49, 363-7; discussion 367-9	3.2 42
57	Deep Brain Stimulator Electrodes Used for Lesioning: Proof of Principle. <i>Neurosurgery</i> , 2001 , 49, 363-369	3.2 31
56	Relationship of lesion location to cognitive outcome following microelectrode-guided pallidotomy for Parkinson's disease: support for the existence of cognitive circuits in the human pallidum. <i>Brain</i> , 2000 , 123 (Pt 4), 746-58	11.2 79
55	Long-term follow-up of unilateral pallidotomy in advanced Parkinson's disease. <i>New England Journal of Medicine</i> , 2000 , 342, 1708-14	59.2 239
54	Surgery for Parkinson disease: A critical evaluation of the state of the art. <i>Archives of Neurology</i> , 2000 , 57, 1118-25	72
53	Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson's disease. <i>Brain and Cognition</i> , 2000 , 42, 324-47	2.7 229
52	A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. <i>New England Journal of Medicine</i> , 2000 , 342, 1484-91	59.2 1253
51	Relationship of lesion location to clinical outcome following microelectrode-guided pallidotomy for Parkinson's disease. <i>Brain</i> , 1999 , 122 (Pt 3), 405-16	11.2 122
50	Historical and clinical features of psychogenic tremor: a review of 70 cases. <i>Canadian Journal of Neurological Sciences</i> , 1999 , 26, 190-5	1 89
49	Variability in lesion location after microelectrode-guided pallidotomy for Parkinson's disease: anatomical, physiological, and technical factors that determine lesion distribution. <i>Journal of Neurosurgery</i> , 1999 , 90, 468-77	3.2 34

48	Motor neuron disease-inclusion dementia presenting as cortical-basal ganglionic degeneration. <i>Movement Disorders</i> , 1999 , 14, 674-80	7	53
47	New use for an old drug: amantadine benefits levodopa-induced dyskinesia. <i>Movement Disorders</i> , 1998 , 13, 851	7	44
46	New developments in understanding the etiology of Parkinson's disease and in its treatment. <i>Current Opinion in Neurobiology</i> , 1998 , 8, 783-90	7.6	74
45	Pallidotomy for tremor. <i>Movement Disorders</i> , 1998 , 13 Suppl 3, 107-10	7	13
44	Corticobasal ganglionic degeneration and progressive supranuclear palsy presenting with cognitive decline. <i>Brain Pathology</i> , 1998 , 8, 355-65	6	74
43	Parkinson's disease. First of two parts. <i>New England Journal of Medicine</i> , 1998 , 339, 1044-53	59.2	1636
42	Parkinson's disease. Second of two parts. <i>New England Journal of Medicine</i> , 1998 , 339, 1130-43	59.2	972
41	Pallidal stimulation in Parkinson's disease patients with a prior unilateral pallidotomy. <i>Canadian Journal of Neurological Sciences</i> , 1998 , 25, 300-5	1	69
40	Microelectrode recordings define the ventral posteromedial pallidotomy target. <i>Stereotactic and Functional Neurosurgery</i> , 1998 , 71, 153-63	1.6	21
39	Pallidotomy for Parkinson's Disease. <i>Neurosurgery Clinics of North America</i> , 1998 , 9, 325-336	4	40
38	Posteroventral medial pallidotomy in advanced Parkinson's disease. <i>New England Journal of Medicine</i> , 1997 , 337, 1036-42	59.2	392
37	Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. <i>Nature Medicine</i> , 1997 , 3, 671-4	50.5	184
36	Neuropsychological and behavioral changes and weight gain after medial pallidotomy. <i>Annals of Neurology</i> , 1997 , 41, 834-6	9.4	42
35	Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. <i>Movement Disorders</i> , 1997 , 12, 570-5	7	147
34	Globus pallidus internus pallidotomy for generalized dystonia. <i>Movement Disorders</i> , 1997 , 12, 865-70	7	329
33	Perioperative problems in Parkinson's disease and their management: apomorphine with rectal domperidone. <i>Canadian Journal of Neurological Sciences</i> , 1996 , 23, 198-203	1	35
32	Idiopathic generalized myokymia (Isaacs' syndrome) with hand posturing resembling dystonia. <i>Movement Disorders</i> , 1996 , 11, 448-9	7	14
31	Psychogenic dystonia: a review of 18 cases. <i>Canadian Journal of Neurological Sciences</i> , 1995 , 22, 136-43	1	118

30	"Weight-holding tremor": an unusual task-specific form of essential tremor?. <i>Movement Disorders</i> , 1995 , 10, 228-9	7	4
29	The classification of akathisia. <i>Movement Disorders</i> , 1995 , 10, 235-7	7	7
28	Hemiatrophy, juvenile-onset exertional alternating leg paresis, hypotonia, and hemidystonia and adult-onset hemiparkinsonism: the spectrum of hemiparkinsonism-hemiatrophy syndrome. <i>Movement Disorders</i> , 1995 , 10, 489-95	7	29
27	The core assessment program for intracerebral transplantation. <i>Movement Disorders</i> , 1995 , 10, 527-8	7	30
26	Chronic acquired hepatocerebral degeneration: case reports and new insights. <i>Movement Disorders</i> , 1995 , 10, 714-22	7	72
25	Withdrawal akathisia: case reports and a proposed classification of chronic akathisia. <i>Movement Disorders</i> , 1994 , 9, 188-92	7	29
24	What is it? Case 1, 1994: rapidly progressive aphasia, apraxia, dementia, myoclonus, and parkinsonism. <i>Movement Disorders</i> , 1994 , 9, 358-66	7	16
23	Parkinsonian syndromes associated with hydrocephalus: case reports, a review of the literature, and pathophysiological hypotheses. <i>Movement Disorders</i> , 1994 , 9, 508-20	7	168
22	Striatonigral degeneration: iron deposition in putamen correlates with the slit-like void signal of magnetic resonance imaging. <i>Canadian Journal of Neurological Sciences</i> , 1994 , 21, 311-8	1	50
21	Parietal Pick's disease mimicking cortical-basal ganglionic degeneration. <i>Neurology</i> , 1994 , 44, 1436-40	6.5	71
20	Hemiballism in multiple sclerosis. <i>Movement Disorders</i> , 1988 , 3, 88-94	7	63
19	Manipulating the dopaminergic system in Parkinson's disease 1987 , 32, 51-76		5
18	High dose anticholinergic therapy in adult dystonia. <i>Canadian Journal of Neurological Sciences</i> , 1986 , 13, 42-6	1	33
17	Persistent hemiballismus with lesions outside the subthalamic nucleus. <i>Canadian Journal of Neurological Sciences</i> , 1985 , 12, 125-8	1	41
16	Treatment of Parkinson's disease with agents other than levodopa and dopamine agonists: controversies and new approaches. <i>Canadian Journal of Neurological Sciences</i> , 1984 , 11, 210-20	1	34
15	Alpha methylparatyrosine and tetrabenazine in movement disorders. <i>Clinical Neuropharmacology</i> , 1982 , 5, 375-87	1.4	21
14	Anticholinergics in adult-onset focal dystonia. <i>Canadian Journal of Neurological Sciences</i> , 1982 , 9, 313-9	1	42
13	Lessons learned: neuroprotective trials in Parkinson's disease 265-279		

- 12 The Clinical Spectrum of Functional/Psychogenic Dystonia 217-223
- 11 Assessment of Non-Motor Features of Parkinson's Disease: Scales and Rating Tools 111-125
- 10 Neuropsychologic Features of Parkinson's Dementias 145-152
- 9 Sexual Dysfunction 296-303
- 8 Prospects for Neuroprotective Therapies that can Modulate Non-Dopaminergic Features in Parkinson's Disease 455-461
- 7 Surgery for Non-Dopaminergic and Non-Motor Features of Parkinson's Disease 409-415
- 6 Functional Anatomy of the Motor and Non-Motor Circuitry of the Basal Ganglia 32-55
- 5 Animal Models of Parkinson's Disease: The Non-Motor and Non-Dopaminergic Features 79-92
- 4 Gait, Postural Instability, and Freezing 261-373 1
- 3 Clinical Trial Measures of the Non-Motor Features of Parkinson's Disease 126-133
- 2 Treatment of Dementia Associated with Parkinson's Disease 163-169
- 1 Non-Dopaminergic Pathology of Parkinson's Disease 15-31 3